LifeArc Ventures Scales Global VC Portfolio in Life Sciences
London, United Kingdom | January 29, 2026 — LifeArc Ventures, the venture capital arm of medical research organization LifeArc,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
London, United Kingdom | January 29, 2026 — LifeArc Ventures, the venture capital arm of medical research organization LifeArc,...
Vancouver, British Columbia, December 18, 2025 — Restart Life Sciences Corp., a Canadian-based life sciences company, has successfully closed...
IRVINE, CA — November 14, 2025 — AEON Biopharma announced its third-quarter 2025 financial results, highlighting strong operational progress,...
BRISBANE, CA – November 13, 2025 — Gate Bioscience announced the closing of an oversubscribed $65 million Series B...
PARIS, Sept. 24, 2025 — Sanofi announced a $625 million capital expansion for its corporate venture fund, Sanofi Ventures,...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...
